- Home
- INVA vs NUVB Comparison
INVA vs NUVB Comparison
Compare INVA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVA
- NUVB
- Stock Information
- Founded
- INVA 1996
- NUVB 2018
- Country
- INVA United States
- NUVB United States
- Employees
- INVA N/A
- NUVB N/A
- Industry
- INVA Biotechnology: Pharmaceutical Preparations
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- INVA Health Care
- NUVB Health Care
- Exchange
- INVA Nasdaq
- NUVB Nasdaq
- Market Cap
- INVA 1.1B
- NUVB 1.1B
- IPO Year
- INVA 2004
- NUVB N/A
- Fundamental
- Price
- INVA $17.71
- NUVB $5.28
- Analyst Decision
- INVA Buy
- NUVB Strong Buy
- Analyst Count
- INVA 5
- NUVB 7
- Target Price
- INVA $35.60
- NUVB $8.43
- AVG Volume (30 Days)
- INVA 767.7K
- NUVB 8.2M
- Earning Date
- INVA 11-06-2025
- NUVB 11-03-2025
- Dividend Yield
- INVA N/A
- NUVB N/A
- EPS Growth
- INVA N/A
- NUVB N/A
- EPS
- INVA 0.53
- NUVB N/A
- Revenue
- INVA $370,229,000.00
- NUVB $14,355,000.00
- Revenue This Year
- INVA $7.98
- NUVB $283.91
- Revenue Next Year
- INVA $11.60
- NUVB $340.13
- P/E Ratio
- INVA $32.96
- NUVB N/A
- Revenue Growth
- INVA 12.02
- NUVB 900.35
- 52 Week Low
- INVA $16.52
- NUVB $1.54
- 52 Week High
- INVA $22.00
- NUVB $5.55
- Technical
- Relative Strength Index (RSI)
- INVA 46.40
- NUVB 76.51
- Support Level
- INVA $17.45
- NUVB $3.36
- Resistance Level
- INVA $18.45
- NUVB $5.55
- Average True Range (ATR)
- INVA 0.50
- NUVB 0.32
- MACD
- INVA 0.12
- NUVB 0.14
- Stochastic Oscillator
- INVA 52.42
- NUVB 87.44
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.